Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression

Mandi Murph, Gordon B. Mills

Research output: Contribution to journalArticle

49 Scopus citations

Abstract

The bioactive lipids lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), the enzymes that generate and degrade them, and the receptors that receive their signals are all potential therapeutic targets in cancer. LPA and S1P signalling pathways can modulate a range of cellular processes that contribute to tumourigenesis, such as proliferation and motility, and components of the signalling pathways often show aberrant expression and altered activity upon malignant transformation. This article reviews LPA- and S1P-mediated activities that might contribute to the aetiology of cancer, and examines the potential of the many antagonists that have been developed to inhibit LPA and S1P signalling pathways. In addition, the outcomes of various clinical trials using LPA- and S1P-associated targets in cancer and other diseases are described, and future directions are discussed.

Original languageEnglish (US)
Pages (from-to)1-18
Number of pages18
JournalExpert reviews in molecular medicine
Volume9
Issue number28
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Fingerprint Dive into the research topics of 'Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression'. Together they form a unique fingerprint.

  • Cite this